Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK.

Saved in:
Bibliographic Details
Title: Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK.
Authors: Vlachaki I; Menarini Ricerche SpA, Athens, Greece., Zinzi D; Menarini Ricerche SpA, Florence, Italy., Falla E; Real World Solutions, IQVIA Ltd, 37 North Wharf Road, London, W21AF, UK. edel.falla@iqvia.com., Mantopoulos T; Real World Solutions, IQVIA Ltd, Athens, Greece., Guy H; FIECON Ltd, St Albans, UK., Jandu J; FIECON Ltd, St Albans, UK., Dodgson A; Public Health England, Manchester, UK.
Source: The European journal of health economics : HEPAC : health economics in prevention and care [Eur J Health Econ] 2022 Apr; Vol. 23 (3), pp. 537-549. Date of Electronic Publication: 2021 Sep 21.
Publication Type: Journal Article
Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 101134867 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-7601 (Electronic) Linking ISSN: 16187598 NLM ISO Abbreviation: Eur J Health Econ Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1618-7601
DOI:10.1007/s10198-021-01375-0